Roth Capital Estimates CervoMed’s Q3 Earnings (NASDAQ:CRVO)

CervoMed Inc. (NASDAQ:CRVO) – Analysts at Roth Capital lowered their Q3 2025 earnings per share (EPS) estimates for shares of CervoMed in a research report issued to clients and investors on Monday, August 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings of ($0.76) per share for the quarter, down from their prior forecast of ($0.50). Roth Capital currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($2.51) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.71) EPS.

A number of other analysts have also commented on the company. Chardan Capital reissued a “buy” rating and issued a $15.00 target price on shares of CervoMed in a report on Monday. D. Boral Capital lifted their target price on CervoMed from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday. Finally, Canaccord Genuity Group lifted their target price on CervoMed from $21.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.43.

CervoMed Trading Up 5.7%

CervoMed stock opened at $10.19 on Thursday. The firm has a market cap of $94.26 million, a price-to-earnings ratio of -3.90 and a beta of -0.79. The stock has a fifty day simple moving average of $7.69 and a two-hundred day simple moving average of $7.11. CervoMed has a 12 month low of $1.80 and a 12 month high of $20.63.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.13). The business had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.45 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%.

Hedge Funds Weigh In On CervoMed

Hedge funds and other institutional investors have recently modified their holdings of the company. Woodline Partners LP bought a new position in shares of CervoMed during the 4th quarter valued at $175,000. Rhumbline Advisers lifted its holdings in shares of CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after buying an additional 1,526 shares during the period. BNP Paribas Financial Markets bought a new position in shares of CervoMed during the 4th quarter valued at $32,000. Citizens Financial Group Inc. RI bought a new position in shares of CervoMed during the 1st quarter valued at $244,000. Finally, Nuveen Asset Management LLC lifted its holdings in shares of CervoMed by 113.6% during the 4th quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after buying an additional 22,104 shares during the period. 25.15% of the stock is owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.